Cambridge, Massachusetts-based Aviceda reported proof-of-concept data with AVD-104 from a phase 2a trial in early 2024 that suggested it was able to slow down GA lesions in the eye and preserve or ...

The 2025 NFL schedule has been released and owners are already thinking about their upcoming 2025 Fantasy football draft prep and potential roster construction. After months of speculation, wide ...